AAAna Paula Pinto de AraújO

Ana Paula Pinto de AraújO

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Paula Pinto de AraújO has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cannabigerol Enhances Muscle Strength and Performance in Dexamethasone-Treated Mice

    by Izabel Feltrin Fabro, Tatyana Nery, Ana Paula Pinto de AraújO, Amanda Leite Bastos Pereira, Francielly Andressa Felipetti, Aderbal Silva Aguiar Jr

    Sarcopenia is a major clinical condition associated with aging and is characterized by progressive loss of skeletal muscle mass and function. Resistance training is an effective intervention to counteract muscle atrophy; however, strategies that selectively enhance functional performance remain limited. Cannabigerol, a phytocannabinoid that is not a CB1 receptor agonist and therefore lacks psychotomimetic activity, has emerged as a potential modulator of neuromuscular function, although its role in skeletal muscle adaptation remains poorly understood. Here, we investigated the effects of resistance exercise and cannabigerol, alone and in combination, in a dexamethasone-induced model of muscle atrophy in mice. Animals received dexamethasone (20 mg/kg, i.p.) for 12 days and were subsequently subjected to a 4-week ladder-based resistance exercise protocol. Cannabigerol (10 mg/kg, i.p.) was administered on training days. Resistance exercise restored muscle morphology and improved fatigue resistance. In contrast, cannabigerol acted mainly on neuromuscular performance, increasing muscle power while producing only a small increase in fiber cross-sectional area. Cannabigerol potentiated training-induced power output, increasing performance by ∼55% in the first week and up to ∼87% after 4 weeks compared to exercise alone. In addition, cannabigerol increased peak grip strength (∼10%) and lowered post-exercise blood lactate in sedentary animals (∼48%). These findings show that resistance exercise and cannabigerol exert complementary effects on skeletal muscle─exercise promoting structural recovery and cannabigerol enhancing neuromuscular performance and lowering post-exercise lactate─and support further investigation of cannabigerol as an adjunct to exercise in glucocorticoid-induced muscle atrophy.

  • Open Access

    Purinergic P2X7 Receptor Antagonism Impairs Aerobic Capacity without Detectable Effect on Cardiac Adaptation to Exercise in Mice

    by Naiara de Souza Santos, Izabel Feltrin Fabro, Ana Paula Pinto de AraújO, Beatriz Carminati dos Santos, Tatyana Nery, SávIo de Almeida Ramos, Izabely Guedes da Rosa, Francielly Andressa Felipetti, Amanda Leite Bastos-Pereira, Aderbal S. Aguiar

    Adenosine triphosphate (ATP) signaling through the P2X7 receptor is an emerging determinant of mitochondrial energy metabolism and physical fitness, and the receptor is increasingly targeted pharmacologically for its role in inflammation. Whether systemic P2X7 antagonism affects aerobic capacity and the structural adaptation of the heart to exercise is unknown. Adult male Swiss mice were studied in a 2 × 2 factorial design crossing physical conditioning (sedentary or exercised) with treatment (saline or the P2X7 antagonist Brilliant Blue G, BBG; 50 mg/kg). Exercised animals trained on a treadmill on alternate days over approximately 4 weeks; maximal oxygen uptake (V̇O2max) and power were measured by incremental treadmill ergospirometry, and myocardial cardiomyocyte volume density (Vv) was quantified by design-based stereology. Aerobic training increased V̇O2max and cardiomyocyte Vv. BBG reduced V̇O2max and peak power independently of training and produced a deficit that widened progressively with workload across the incremental test, indicating a demand-dependent limitation of oxidative performance. Critically, BBG did not detectably alter the exercise-induced increase in cardiomyocyte Vv and showed no interaction with training; motor coordination, locomotor and exploratory behavior, blood lactate, and body mass were also unaffected. P2X7 antagonism thus impairs aerobic capacity without detectable blunting of the structural response of the heart to exercise. This functional–structural dissociation points to a metabolic process, plausibly mitochondrial, rather than to cardiac remodeling, although the present sample size bounds rather than excludes an effect on cardiac adaptation, and indicates that P2X7-directed therapies may reduce exercise capacity without producing overt cardiac structural change.

  • Open Access

    Cannabidiol in Sports: A Brazilian Perspective

    by Tatyana Nery, Jose Wilson Nv Andrade, Jimmy Fardin Rocha, Ana Paula Pinto de Araújo, Aderbal Silva Aguiar Jr

    This Viewpoint examines the emerging role of cannabidiol (CBD) in sports medicine, with a particular emphasis on its potential to support athlete health through indirect mechanisms. Rather than acting as a direct performance enhancer, CBD may contribute to improved readiness for training and competition by promoting better sleep, alleviating anxiety, and accelerating recovery. We also discuss challenges for antidoping compliance, including product contamination and regulatory gaps in Brazil, and highlight CBD's promise as a safer alternative to opioids for pain management in athletes.